Maria Ladea1, Mihai Bran. 1. Clinical Psychiatric Hospital, Prof. Dr. Alexandru Obregia, Berceni Street 10-12, 041902 Bucharest, Romania. marialadea@gmail.com
Abstract
BACKGROUND: Recent studies suggest the important role of brain derived neurotrophic factor (BDNF) in the etiopathogenesis of major depressive disorder (MDD) and the mechanism of action of antidepressants. This study aimed to correlate serum levels of BDNF and clinical symptoms in patients with MDD before and after 6 months treatment with escitalopram. SUBJECTS AND METHODS: Twenty women diagnosed with MDD and 20 aged-matched healthy female controls were recruited. The patients received escitalopram 10-20 mg/day. BDNF serum levels were measured at inclusion, week 4, week 12 and week 24. The Montgomery-Åsberg Depression Rating Scale (MADRS) was used to assess the severity of depressive symptoms and the clinical evolution of patients. Statistical analysis was performed using both observed cases and last observation carried forward. RESULTS: At baseline, low serum levels of BDNF were associated with MDD. In women with MDD, escitalopram seems to have a positive effect on BDNF serum levels in parallel with the clinical response. CONCLUSIONS: This study suggests that a good clinical evolution under treatment with escitalopram might be associated with increases of BDNF levels in female patients.
BACKGROUND: Recent studies suggest the important role of brain derived neurotrophic factor (BDNF) in the etiopathogenesis of major depressive disorder (MDD) and the mechanism of action of antidepressants. This study aimed to correlate serum levels of BDNF and clinical symptoms in patients with MDD before and after 6 months treatment with escitalopram. SUBJECTS AND METHODS: Twenty women diagnosed with MDD and 20 aged-matched healthy female controls were recruited. The patients received escitalopram 10-20 mg/day. BDNF serum levels were measured at inclusion, week 4, week 12 and week 24. The Montgomery-Åsberg Depression Rating Scale (MADRS) was used to assess the severity of depressive symptoms and the clinical evolution of patients. Statistical analysis was performed using both observed cases and last observation carried forward. RESULTS: At baseline, low serum levels of BDNF were associated with MDD. In women with MDD, escitalopram seems to have a positive effect on BDNF serum levels in parallel with the clinical response. CONCLUSIONS: This study suggests that a good clinical evolution under treatment with escitalopram might be associated with increases of BDNF levels in female patients.
Authors: Anatoly Kreinin; Serah Lisson; Elimelech Nesher; Jenny Schneider; Josef Bergman; Kamal Farhat; Joseph Farah; Flavio Lejbkowicz; Gal Yadid; Leon Raskin; Igor Koman; Albert Pinhasov Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Md Prova Zaman Emon; Rajesh Das; Nuruna Lovely Nishuty; M M A Shalahuddin Qusar; Mohiuddin Ahmed Bhuiyan; Md Rabiul Islam Journal: BMC Res Notes Date: 2020-02-21